Heart transplant drug may also fight skin cancer
NCT ID NCT00799188
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested whether the drug everolimus can reduce new skin cancers in heart transplant patients who already had skin cancer. 175 participants received either everolimus or standard immunosuppressants. The goal was to see if everolimus lowers the number of new skin tumors needing surgery over two years.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- everolimus
- What this could lead to
- If successful, this could offer heart transplant patients a way to lower their risk of recurrent skin cancers while maintaining graft function.
- What could go wrong
- This is a completed phase 3 trial, but results may not apply to all patients. Everolimus has side effects and may not prevent all skin cancers or other cancers.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BASAL CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
HOSPICES CIVILS de LYON
Lyon, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can Pre-Surgery immunotherapy prime the immune system to fight head and neck cancer?
- Can your genes predict your melanoma risk?
- Glowing cancer cells: a new way to see tumors during surgery?
- A UV photo and a cheek swab may be the keys to stopping sunburn before it starts
- Botox before the knife: could a Pre-Surgery injection lead to Better-Looking scars?
- Could a lighter immunotherapy schedule keep advanced cancers in check?